^
Association details:
| Biomarker: | ALK positive + MYC amplification + CCND1 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
P84.14 - Identification of Mechanisms of Resistance to ALK Inhibitors. Next-Generation Sequencing-Based Liquid Biopsy Profiling.
Published date:
01/12/2021
Excerpt:
...advanced ALK-positive NSCLC patients, were analyzed by next-generation sequencing (NGS)...c-MYC gain, along with a loss of CCND1 and a FGFR3, were detected in a patient progressing on a first-line treatment with crizotinib.
